Investors & Media

2016 Press Releases

Webcast ImageWebcast
Flex Pharma Inc at the Cantor Fitzgerald 2017 Global Healthcare Conference (Live)
09/25/17 at 3:35 p.m. ET
Flex Pharma Inc at the Cantor Fitzgerald 2017 Global Healthcare Conference
Monday, September 25, 2017 3:35 p.m. ET  
Webcast PresentationHelp Help
Click here for webcast
Add to CalendarHelp Help
Add to Calendar Click here to add this event to your calendar
Keyword Search
 
2017 | 2016 | 2015 | 2014
DateTitle 
11/21/16Flex Pharma to Present at the Piper Jaffray 28th Annual Healthcare Conference
BOSTON--(BUSINESS WIRE)--Nov. 21, 2016-- Click to Tweet Flex Pharma, Inc. (NASDAQ: FLKS) today announced that Company management will present a corporate overview at the Piper Jaffray 28th Annual Healthcare Conference on Wednesday, November 30, 2016 at 3:00 p.m. ET. A live webcast of Flex Pharma’s presentations at these conferences may be accessed in the Investor section of the Company’s website at www.flex-pharma.com. ... 
Printer Friendly Version
11/09/16Flex Pharma to Present at the Jefferies 2016 Healthcare Conference
BOSTON--(BUSINESS WIRE)--Nov. 9, 2016-- Click to Tweet Flex Pharma, Inc. (NASDAQ: FLKS) today announced that Company management will present a corporate overview at the Jefferies 2016 London Healthcare Conference on Wednesday, November 16, 2016 at 8:00 a.m. GMT. A live webcast of Flex Pharma’s presentations at these conferences may be accessed in the Investor section of the Company’s website at www.flex-pharma.com. Please lo... 
Printer Friendly Version
11/02/16Flex Pharma Reports Third Quarter 2016 Financial Results
-- Exploratory Phase 2 MS & ALS Studies with FLX-787 Underway -- -- HOTSHOTTM Net Product Revenue of $586,000 -- Conference Call Scheduled Today at 8:45 a.m. ET BOSTON--(BUSINESS WIRE)--Nov. 2, 2016-- Click to Tweet Flex Pharma, Inc. (NASDAQ: FLKS), a biotechnology company developing innovative and proprietary treatments for nocturnal leg cramps (NLC), spasms associated with severe neuromuscular condit... 
Printer Friendly Version
10/26/16Flex Pharma to Report Third Quarter 2016 Results on November 2, 2016
BOSTON--(BUSINESS WIRE)--Oct. 26, 2016-- Click to Tweet Flex Pharma, Inc. (NASDAQ: FLKS), a biotechnology company developing innovative and proprietary treatments for nocturnal leg cramps (NLC), cramps and spasms associated with severe neuromuscular conditions such as MS and ALS, and exercise-associated muscle cramps, announced today that it will report its financial results for the third quarter ended September 30, 2016 on W... 
Printer Friendly Version
10/13/16Flex Pharma Provides FLX-787 Nocturnal Leg Cramp Regulatory and Clinical Update
-- Efficacy Signals Seen in Subanalyses of Exploratory Human Studies of FLX-787 -- -- Parallel Design Phase 2 Trial Planned for First Half 2017 Based upon FDA Pre-IND Responses -- -- Conference Call and Webcast today at 8:45 a.m. ET -- BOSTON--(BUSINESS WIRE)--Oct. 13, 2016-- Click to Tweet Flex Pharma, Inc. (NASDAQ: FLKS) today provided a nocturnal leg cramp (NLC) regulatory and clinical update for... 
Printer Friendly Version
09/13/16Flex Pharma Initiates Phase 2 Efficacy Study in Amyotrophic Lateral Sclerosis
-- Tablet Formulation of FLX-787, A Single Molecule, Synthesized, TRP Ion Channel Activator, in Randomized, Controlled, Cross-over Study -- BOSTON--(BUSINESS WIRE)--Sep. 13, 2016-- Click to Tweet this News Flex Pharma, Inc. (NASDAQ: FLKS) today announced that it has initiated a Phase 2 efficacy study in amyotrophic lateral sclerosis (ALS) patients in Australia with FLX-787, its chemically synthesized, single molecule, ... 
Printer Friendly Version
09/01/16Flex Pharma Presenting at Upcoming Investor Conferences in September 2016
BOSTON--(BUSINESS WIRE)--Sep. 1, 2016-- Click to Tweet Flex Pharma, Inc. (NASDAQ: FLKS) today announced that it will present a corporate overview at the following upcoming investor conferences in September: The BioCentury NewsMakers Conference on September 9, 2016 at 11:30 a.m. in New York, NY; The Rodman & Renshaw 18th Annual Global Investment Conference on September 13, 2016 at 9:... 
Printer Friendly Version
08/26/16Flex Pharma Announces Scientific Advisory Board Appointment and Management Change
-- W. Larry Kenney, Ph.D., Penn State University Professor of Physiology and Kinesiology, Joins Scientific Advisory Board -- -- Kathie Lindemann, COO, Continues Leading Consumer; Marina Hahn Transitions to Advisor -- BOSTON--(BUSINESS WIRE)--Aug. 26, 2016-- Click to Tweet Flex Pharma, Inc. (NASDAQ: FLKS) announced today that W. Larry Kenney, Ph.D., Professor of Physiology and Kinesiology at Penn State Univ... 
Printer Friendly Version
08/03/16Flex Pharma Reports Second Quarter 2016 Financial Results
-- Single Agent Human Efficacy Study in NLC Fully Enrolled Ahead of Plan with Topline Results Expected by Year End -- -- Phase 2 MS Study of FLX-787 Initiated in June; Phase 2 ALS Study to Start in the Coming Months -- -- First Consumer Product Scientifically Proven to Treat and Prevent Muscle Cramps Launched in June -- Conference Call Scheduled Today at 8:45 a.m. ET BOSTON--(BUSINESS WIRE)--Aug. 3, 2016-- Click ... 
Printer Friendly Version
07/27/16Flex Pharma to Report Second Quarter 2016 Results on August 3, 2016
BOSTON--(BUSINESS WIRE)--Jul. 27, 2016-- Click to Tweet Flex Pharma, Inc. (NASDAQ: FLKS), a biotechnology company developing innovative and proprietary treatments for nocturnal leg cramps (NLC), cramps and spasms associated with severe neuromuscular conditions such as MS and ALS, and exercise-associated muscle cramps, announced today that it will report its financial results for the second quarter ended June 30, 2016 on Wedne... 
Printer Friendly Version
07/26/16Flex Pharma Completes Enrollment of Human Proof-of Concept Efficacy Study in Nocturnal Leg Cramps
-- Topline Results Expected Ahead of Plan, by Year End, for Single Molecule TRP Ion Channel Activator in Randomized, Blinded, Controlled, Cross-over Study -- BOSTON--(BUSINESS WIRE)--Jul. 26, 2016-- Click to Tweet this News Flex Pharma, Inc. (NASDAQ: FLKS) today announced that it has completed enrollment of its human proof-of-concept efficacy study in nocturnal leg cramps (NLC) with its chemically synthesized, single mole... 
Printer Friendly Version
07/06/16Flex Pharma to Present at the Cantor Fitzgerald Healthcare Conference
BOSTON--(BUSINESS WIRE)--Jul. 6, 2016-- Click to Tweet Flex Pharma, Inc. (NASDAQ: FLKS) today announced that Company management will present a corporate overview at the 2nd Annual Cantor Fitzgerald Healthcare Conference on Wednesday, July 13, 2016 at 11:45 a.m. A live webcast of Flex Pharma’s presentations at these conferences may be accessed in the Investor section of the Company’s website at www.flex-pharma.com. Ple... 
Printer Friendly Version
06/15/16Flex Pharma Initiates Phase 2 Efficacy Study in Multiple Sclerosis
-- FLX-787, A Single Molecule, Synthesized, TRP Ion Channel Activator, in Randomized, Controlled, Cross-over Study -- BOSTON--(BUSINESS WIRE)--Jun. 15, 2016-- Click to Tweet this News Flex Pharma, Inc. (NASDAQ: FLKS) today announced that it has initiated a Phase 2 efficacy study in multiple sclerosis (MS) patients in Australia. The randomized, controlled, blinded, cross-over study is designed to evaluate the safety and ef... 
Printer Friendly Version
06/03/16Flex Pharma Presenting at Upcoming Investor Conferences in June 2016
BOSTON--(BUSINESS WIRE)--Jun. 3, 2016-- Click to Tweet Flex Pharma, Inc. (NASDAQ: FLKS) today announced that it will present a corporate overview at the following upcoming investor conferences in June: The Jefferies 2016 Healthcare Conference on June 9, 2016 at 11:30 a.m. in New York, NY; The 36th Annual Piper Jaffray Consumer Conference on June 15, 2016 at 10:50 a.m. in New York, NY; ... 
Printer Friendly Version
06/02/16Flex Pharma Launches First Consumer Product Scientifically Proven to Prevent and Treat Muscle Cramps
-- Harvard Medical School Professor, Dr. Bruce Bean, and Flex CMO, Dr. Tom Wessel, Presenting at American College of Sport Medicine Symposium -- BOSTON--(BUSINESS WIRE)--Jun. 2, 2016-- Flex Pharma, Inc. (NASDAQ: FLKS): Click to Tweet this News Flex Pharma, Inc. (NASDAQ: FLKS), today announced that it has launched its cornerstone consumer product, HOTSHOT™, the first scientifically proven formula to prevent ... 
Printer Friendly Version
05/25/16Flex Pharma Initiates Human Efficacy Study with Single Molecule Tablet in Nocturnal Leg Cramps
-- Single Molecule TRP Ion Channel Agonist in Randomized, Blinded, Controlled, Cross-over Study -- BOSTON--(BUSINESS WIRE)--May 25, 2016-- Click to Tweet this News Flex Pharma, Inc. (NASDAQ: FLKS) today announced that it has initiated a human proof-of-concept efficacy study in nocturnal leg cramps (NLC) with its chemically synthesized, single molecule, transient receptor potential (TRP) ion channel activator, formulated a... 
Printer Friendly Version
05/04/16Flex Pharma Reports First Quarter 2016 Financial Results
-- Initiating Single Agent Human Efficacy Studies in NLC, MS and ALS this year -- -- Launching First Consumer Product Scientifically Proven to Treat and Prevent Muscle Cramps -- Conference Call Scheduled Today at 8:45 a.m. ET BOSTON--(BUSINESS WIRE)--May 4, 2016-- Click to Tweet Flex Pharma, Inc. (NASDAQ: FLKS), a biotechnology company developing innovative and proprietary treatments for nocturnal leg cram... 
Printer Friendly Version
04/27/16Flex Pharma to Report First Quarter 2016 Results on May 4, 2016
BOSTON--(BUSINESS WIRE)--Apr. 27, 2016-- Click to Tweet Flex Pharma, Inc. (NASDAQ: FLKS), a biotechnology company developing innovative and proprietary treatments for nocturnal leg cramps (NLC), spasms associated with severe neuromuscular conditions such as MS and ALS, and exercise-associated muscle cramps, announced today that it will report its financial results for the first quarter ended March 31, 2016 on Wednesday, May 4... 
Printer Friendly Version
04/19/16Flex Pharma’s Positive Human NLC Study Selected for Presentation at AAN Annual Meeting
-- Statistically Significant Efficacy Demonstrated in Randomized, Controlled, Blinded Nocturnal Leg Cramp Study -- BOSTON--(BUSINESS WIRE)--Apr. 19, 2016-- Click to Tweet Flex Pharma, Inc. (NASDAQ: FLKS) announced that results from its recently completed study in nocturnal leg cramps (NLC) will be presented later today at the American Academy of Neurology (AAN) 68th Annual Meeting in Vancouver, B.C., Canada. As one of onl... 
Printer Friendly Version
04/06/16Flex Pharma Collaborator Penn State Presents Positive Human Muscle Cramp Data
-- Presentation at Experimental Biology 2016 Conference Shows Positive Effect on Athletic Human Muscle Cramps -- BOSTON--(BUSINESS WIRE)--Apr. 6, 2016-- Click to Tweet Flex Pharma, Inc. (NASDAQ: FLKS) announced today that results from a study showing that its proprietary formulation of TRPA1 and TRPV1 activators prevented volitional muscle cramps will be presented today at the Experimental Biology conference. In the study... 
Printer Friendly Version
03/14/16Flex Pharma Positive Human NLC Study Selected for Late-Breaking Presentation at AAN Annual Meeting
-- Oral Presentation and Poster of Study Results on April 19, 2016 -- BOSTON--(BUSINESS WIRE)--Mar. 14, 2016-- Flex Pharma, Inc. (NASDAQ: FLKS) announced today that the recently completed study in nocturnal leg cramps (NLC) has been selected for late-breaking oral and poster presentations at the American Academy of Neurology (AAN) 68th Annual Meeting being held in Vancouver, B.C., Canada. Only 14 abstracts are selected as late-breaking... 
Printer Friendly Version
03/08/16Flex Pharma Reports Year End 2015 Financial Results
Conference Call Scheduled Today at 8:30 a.m. ET BOSTON--(BUSINESS WIRE)--Mar. 8, 2016-- Click to Tweet Flex Pharma, Inc. (NASDAQ: FLKS), a biotechnology company developing innovative and proprietary treatments for nocturnal leg cramps (NLC), spasms associated with severe neuromuscular conditions, and exercise-associated muscle cramps, today reported financial results for the year ended December 31, 2015 and provided an ... 
Printer Friendly Version
03/07/16Michelle V. Stacy Joins Flex Pharma’s Board of Directors
- Former Keurig President - BOSTON--(BUSINESS WIRE)--Mar. 7, 2016-- Click to Tweet Flex Pharma, Inc. (NASDAQ: FLKS), a biotechnology company developing innovative and proprietary treatments for nocturnal leg cramps (NLC), spasms associated with severe neuromuscular conditions, and exercise-associated muscle cramps, announced today that Michelle V. Stacy, former President of Keurig Inc., has joined its Board of Dire... 
Printer Friendly Version
03/01/16Flex Pharma to Report Full Year 2015 Results on March 8, 2016
BOSTON--(BUSINESS WIRE)--Mar. 1, 2016-- Click to Tweet Flex Pharma, Inc. (NASDAQ: FLKS), a biotechnology company developing innovative and proprietary treatments for nocturnal leg cramps (NLC), spasms associated with severe neuromuscular conditions, and exercise-associated muscle cramps, announced today that it will report its financial results for the year ended December 31, 2015 on Tuesday, March 8, 2016 before the U.S. fin... 
Printer Friendly Version
02/02/16Flex Pharma Announces Positive Human Efficacy in Nocturnal Leg Cramp Study
-- Statistically Significant Efficacy Demonstrated on Key Endpoints in Randomized, Controlled, Blinded Study -- -- Company to Host Conference Call and Webcast Tuesday Feb 2nd at 9am -- BOSTON--(BUSINESS WIRE)--Feb. 2, 2016-- Click to Tweet Flex Pharma, Inc. (NASDAQ: FLKS), a biotechnology company developing innovative and proprietary treatments for nocturnal leg cramps (NLC), spasms associated with severe n... 
Printer Friendly Version
01/06/16Enrollment Completed in Flex Pharma’s Exploratory Human Nocturnal Leg Cramp Study
-- Company Expects to Report Results Q1 2016 -- BOSTON--(BUSINESS WIRE)--Jan. 6, 2016-- Flex Pharma, Inc. (NASDAQ: FLKS): Click to Tweet this News Flex Pharma, Inc. (NASDAQ: FLKS), a biotechnology company developing innovative and proprietary treatments for spasms associated with severe neuromuscular conditions, nocturnal leg cramps and exercise-associated muscle cramps, announced today that enrollment has been co... 
Printer Friendly Version